The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (NASDAQ: VRCA) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Verrica’s proprietary applicator for VP-102 posed safety risks to patients if the instructions were not followed exactly. Based on this risk, the Company built additional user features into the applicator. The applicator change would in turn require additional testing and supportive data. This additional work was likely to delay the regulatory approval of VP-102. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Verrica, investors suffered damages.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at email@example.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.